Oral anti-alpha4-integrin in development


Firategrast, an oral formulation of a natalizumab-like small molecule, produces a significant reduction in MRI lesions, according to the results of a phase II study (Miller et al. Lancet Neurol 2012; epublished January 5, 2012).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page